Skip to main content
607 search results for:

Trastuzumab Deruxtecan 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 01-04-2024 | Trastuzumab | News

    Trastuzumab-deruxtecan

    Various toxicities
  2. 01-04-2024 | Trastuzumab | News

    Trastuzumab-deruxtecan

    Interstitial lung disease and nausea
  3. 01-04-2024 | Trastuzumab Deruxtecan | News

    Trastuzumab-deruxtecan

    Interstitial lung disease
  4. 01-04-2024 | Trastuzumab | News

    Trastuzumab-deruxtecan

    Lack of efficacy
  5. 01-03-2024 | Trastuzumab | News

    Trastuzumab-deruxtecan

    Neutropenia
  6. 01-03-2024 | Trastuzumab | News

    Trastuzumab/trastuzumab-deruxtecan

    Interstitial lung disease and lack of efficacy
  7. Open Access 17-02-2024 | Trastuzumab Deruxtecan | OriginalPaper

    Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model

    Human epidermal growth factor 2 (HER2)-positive breast cancer with lung metastases resistant to targeted agents is a common therapeutic challenge. Absence of preclinical lung metastasis models that are resistant to multiple anti-HER2 targeted …

  8. 01-02-2024 | Trastuzumab | News

    Trastuzumab-deruxtecan

    Interstitial lung disease
  9. 01-02-2024 | Trastuzumab | News

    Trastuzumab-deruxtecan

    Grade 3 neutropenia and interstitial lung disease
  10. Open Access 04-03-2024 | Breast Cancer | OriginalPaper

    Trastuzumab deruxtecan for human epidermal growth factor receptor 2-low advanced or metastatic breast cancer: recommendations from the Japanese Breast Cancer Society Clinical Practice Guidelines

    The Japanese Breast Cancer Society Clinical Practice Guidelines are published as timely guidance on clinical issues in breast cancer treatment in Japan. In the recent edition of these guidelines, we addressed a new clinical question 34 (CQ 34 …

  11. Open Access 09-02-2024 | Trastuzumab Deruxtecan | Online First

    Safety profile of trastuzumab deruxtecan in advanced breast cancer: Expert opinion on adverse event management

    Trastuzumab deruxtecan (T-DXd) is an antibody–drug conjugate that targets human epidermal growth factor receptor 2 (HER2) and has shown promising results in the treatment of advanced/metastatic breast cancer. The objective of this report is to …

  12. 13-12-2023 | Breast Cancer | ReviewPaper

    Exploring DESTINY: the Past, Present, and Future of Trastuzumab Deruxtecan

    Human epidermal growth factor receptor-2 (HER2) directed therapies have greatly improved the prognosis of HER2-positive breast cancer in the early and metastatic settings [ 1 ]. Several classes of anti-HER2 drugs have shown clinical activity and …

  13. Open Access 01-12-2024 | Breast Cancer | OriginalPaper

    Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study)

    Human epidermal growth factor 2 (HER2) is over-expressed and/or amplified in 15–20% of all breast cancers. HER2-targeted therapies, such as the monoclonal antibody trastuzumab, have significantly improved clinical outcomes for patients with …

  14. 01-11-2023 | Trastuzumab | News

    Trastuzumab-deruxtecan

    Pneumocystis jirovecii pneumonia: case report
  15. 14-11-2023 | Trastuzumab Deruxtecan | OriginalPaper

    Cost–utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer in Chinese setting

    Despite significant improvements in healthcare conditions and funding for cancer control, breast cancer (BC) is one of the top five most common cancers in China, alongside lungs, colorectal, stomach, and liver cancers, causing a serious burden of …

  16. 08-11-2023 | Trastuzumab Deruxtecan | ReviewPaper

    Opportunities and Challenges for a Histology-Agnostic Utilization of Trastuzumab Deruxtecan

    The primary tumor source has traditionally guided cancer treatment for advanced-stage tumors, with distinct treatment algorithms developed for each tumor type. In this setting, targeted treatments have been traditionally developed to target …

  17. 05-10-2023 | Trastuzumab Deruxtecan | OriginalPaper

    Disease Severity Modifier in the NICE Single Technology Appraisal of Trastuzumab Deruxtecan: External Assessment Group Perspective

    The National Institute for Health and Care Excellence (NICE) introduced decision-making severity modifiers in their latest methods guidance [ 1 ]. The severity modifier replaces the end-of-life premium criteria. While quality-adjusted life-years …

  18. 01-11-2023 | Trastuzumab | News

    Trastuzumab-deruxtecan

    Lack of efficacy: case report
  19. Open Access 28-10-2023 | Trastuzumab Deruxtecan | Erratum

    Correction to: Clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan

  20. Open Access 14-11-2023 | Trastuzumab Deruxtecan | OriginalPaper

    Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer: a multicenter, open-label, expanded-access study

    Approximately 15% of patients with gastric cancer have human epidermal growth factor receptor 2 (HER2)-positive status [ 1 – 6 ]. Overexpression of HER2 starts a signaling cascade that results in tumor progression [ 7 , 8 ], and thus, HER2 is an …

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.